Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Eli Lilly (Symbol: LLY) entered into oversold territory, hitting an RSI reading of 29.5 ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock is, again, testing multiyear lows. The $700 billion pharmaceutical giant ...

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is selling ...

April 8 - Eli Lilly (NYSE:LLY) shares rose about 5% Tuesday morning after Goldman Sachs (NYSE:GS) upgraded the pharmaceutical giant to Buy from Neutral, citing confidence in its leadership in the fast ...

On Tuesday, Goldman Sachs upgraded shares of Eli Lilly (NYSE:LLY) from Neutral to Buy, while slightly reducing the price target to $888 from $892. The firm's analyst highlighted the pharmaceutical ...

The bottom line: After taking the opportunity to reassess the relative merits of the pipelines of the two firms, we’re raising our fair value estimate for Lilly to $650 per share from $620 and ...